AI Article Synopsis
- Ruxolitinib (RUX) is a kinase inhibitor that suppresses the immune system and is used to treat conditions like polycythemia vera and myelofibrosis.
- Although it can be effective, RUX increases the risk of infections, including bacterial, viral, and fungal.
- A case report highlights a patient's serious fungal infection while on RUX, stressing the importance of monitoring for endemic fungal infections in patients undergoing this treatment.
Article Abstract
Ruxolitinib (RUX) is a kinase inhibitor used in the treatment of various medical conditions and its mechanism of action involves suppression of the immune system. While beneficial in treatment of polycythemia vera, myelofibrosis and other indications, it can also increase a patient's susceptibility to various infections, including bacterial, viral and fungal. We present a case of a patient being treated with RUX who presented with a disseminated fungal infection. This case emphasises the need for vigilance of endemic fungal infections in individuals who are on RUX therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562518 | PMC |
| http://dx.doi.org/10.1136/bcr-2021-243694 | DOI Listing |
Publication Analysis
Top Keywords
polycythemia vera
8
disseminated blastomycosis
4
blastomycosis patient
4
patient polycythemia
4
vera ruxolitinib
4
ruxolitinib ruxolitinib
4
ruxolitinib rux
4
rux kinase
4
kinase inhibitor
4
inhibitor treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!